Evaluating the cost and clinical outcomes of changing type 2 diabetes mellitus patients from current DPP-4 inhibitor treatment to alogliptin in a primary care setting First published 29/04/2019 Last updated 01/04/2024 EU PAS number:EUPAS29153 Study Finalised